Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stopstudy
2023-505143-39-00Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2024
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of estradiol in gender dysphoria (GD), sponsored by Amsterdam University Medical Center. Primary endpoint: Cardiovascular risk determinants. Started Feb 2024; status: completed.
02
Drugs
estradiol
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on 2023-505143-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505143-39-00.